



**Enabling the Evaluation of COVID-19 Vaccines with
Correlates of Protection
Vaccinopolis, University of Antwerp, Belgium
February 16 -17, 2023**

Scientific Committee

Cristina Cassetti

National Institute of Allergy and Infectious Diseases, NIH, U.S.A.

Jakob Cramer

Coalition for Epidemic Preparedness Innovations (CEPI), United Kingdom

Marion Gruber

International AIDS Vaccine Initiative (IAVI), U.S.A.

Adam Hacker

Coalition for Epidemic Preparedness Innovations (CEPI), United Kingdom

Deborah King

Wellcome Trust, United Kingdom

Arnaud Marchant

European Plotkin Institute for Vaccinology (EPIV), Université Libre de Bruxelles (ULB), Belgium

Pieter Neels

Vaccine Advice, Belgium

Stanley Plotkin

University of Pennsylvania, U.S.A.

Pierre Van Damme

European Plotkin Institute for Vaccinology (EPIV); Vaccine & Infectious Disease Institute,
University of Antwerp, Belgium

Joris Vandeputte

International Alliance for Biological Standardization (IABS), Belgium

The aim of the workshop is to review current evidence regarding correlates of protection against COVID-19, identify gaps in knowledge and define research strategies to advance vaccine-induced protection against beta coronaviruses. The meeting will also discuss the role of controlled human infection model studies for the identification of correlates of protection and evaluation of novel vaccines. A multidisciplinary panel of experts will participate in the meeting. Ample time will be given to discussions to generate a common understanding of the topic and define guidelines for the way forward.

Agenda

Day 1 - February 16, 2023

8.00 – 17.50

8.00-9:00 **Registration**

9.00-9.25 **Opening: welcome by Pierre Van Damme and Stanley Plotkin**

IABS, NIH, CEPI and WT to introduce the importance of the topic for their institution.

SESSION 1

9.25-10.25 **Introduction: Why do we need correlates of protection against SARS-CoV-2?**
Chair: Stanley Plotkin, Department of Pediatrics, University of Pennsylvania, U.S.A.

9.25-9.45 Immune effectors controlling SARS-CoV-2 infection, disease and transmission.
Dan Barouch, Beth Israel Deaconess Medical Center, U.S.A. (Remote)

9.45-10.00 Using CoP to license future SARS-COV-2 vaccines.
Marion Gruber, IAVI, U.S.A.

10.00-10.15 Using CoP to guide the use of current SARS-COV-2 vaccines.
Hanna Nohynek, Finnish Institute for Health and Welfare, Finland

10.15-10.35 Break

SESSION 2

10.35-12.30 Serum antibodies.
*Chair: David Goldblatt, Great Ormond Street Institute of Child Health
University College London, United Kingdom*

10:35-10:50 Measurement of serum antibodies
David Montefiori, Duke University, U.S.A (Remote)

10:50- 11:05 Antibody correlates I
Miles Davenport, Kirby Institute, Australia

11:05-11:20 Antibody correlates II
Merryn Voysey, Oxford Vaccine Group, Department of Paediatrics,
University of Oxford

11.20-11:35 Knowledge gaps and future research for antibody CoP
Peter Gilbert, Fred Hutchinson Cancer Research Center, University of
Washington, U.S.A.

11.35-12.30 Panel discussion sessions 1 and 2: Do we have a consensus on the purpose of correlates of protection for COVID-19 vaccines? Do we make the best use of available antibody data? Do we need additional data and for which purpose? Can we define correlates of protection against infection/shedding?

Discussants

Margaret Ackerman, Dartmouth College, U.S.A.

Cristina Cassetti, NIAID, U.S.A.

Marco Cavaleri, EMA, The Netherlands

Adam Hacker, CEPI, United Kingdom

Liz Miller, London School of Hygiene & Tropical Medicine, United Kingdom

Pieter Neels, Vaccine Advice, Belgium

Dean Smith, Health Canada

Jerry Weir, CBER-FDA, U.S.A.

12.30-13.15 Lunch

SESSION 3

13.15-14.45

Circulating T lymphocytes.

Chair: **Arnaud Marchant**, Institute for Medical Immunology (IMI)
Université Libre de Bruxelles

13.15-13.35 The role of T lymphocytes in COVID-19

John Wherry, University of Pennsylvania Institute for Immunology, U.S.A.

13.35-13.55 T cell correlates of protection against SARS-CoV-2

Arnaud Marchant, Institute for Medical Immunology (IMI)
Université Libre de Bruxelles

13.55-14.15 How to measure T lymphocyte response to SARS-CoV-2 and what performance to expect?

Robbert van der Most, BioNTech SE, Germany

14.15-14.45 Panel discussion: Are T cells important to protection against diverse clinical outcomes? Link with Ab? What do available data tell us? Can we use them? What other data do we need and for which purpose? How can other vaccine-preventable disease models inform identification of COVID CoP?

All Speakers

Discussants

Miles Davenport, Kirby Institute, Australia

Martina Sester, Universität des Saarlande, Germany

John Tsang, Yale Center for Systems and Engineering Immunology (CSEI), U.S.A.

SESSION 4

14.45-16.10

Mucosal immunity

Chair: **Cristina Casetti**, NIAID, U.S.A.

14.45-15.05

What are the components of mucosal immunity to SARS-CoV-2
Yongjun Sui, National Cancer Institute, U.S.A.

15.05-15.25

Mucosal correlates of protection against SARS-CoV-2
Ryan Thwaites, Imperial College, United Kingdom (Remote)

15.25-15.50

How to induce mucosal immunity to SARS-CoV-2
Mark Connors, NIAID / Laboratory of Immunoregulation (LIR), U.S.A.

15.50-16.20

Panel discussion: Can we use available data? What other data do we need and for which purpose?
All Speakers
Discussant
Peter Wright, Dartmouth College, U.S.A.

16.20-16.40

Break

SESSION 5

16.40-17.50

T and B Cell Memory.

Chair: **Jakob Cramer**, CEPI, United Kingdom

16.40-17.00

Cellular basis for immunological memory to SARS-CoV-2
Mehul Suthar, Emory University, U.S.A.

17.00-17.20

How to measure immunological memory to SARS-CoV-2?
Alessandro Sette, LaJolla Institute for Immunology, U.S.A.

17.20-18.00

Panel discussion: Could we use immunological memory as a correlate of protection against SARS-CoV-2?
All speakers
Discussants
Antonio Bertoletti, Duke University, Singapore
Merryn Voysey, Oxford Vaccine Group, Department of Paediatrics, University of Oxford

Day 2 – February 17, 2023

8:30-12.00

8:30-9:00 **Registration**

SESSION 6

9.00-10.30 What are the correlates of protection against beta coronavirus/sarbecovirus vaccines?

Chair: **Deborah King**, Wellcome Trust, United Kingdom

9.00-9.20 Engineered immunogens to elicit antibodies with broad reactivity against coronaviruses

Mihai Azoitei, Duke Human Vaccine Institute, U.S.A.

9.20-9.40 Shall we induce a broad T cell response

Antonio Bertoletti, Duke University, Singapore

9.40-10:00 Towards a COVID-19 vaccine to protect against SARS-CoV-2 variants and animal sarbecoviruses without updating

Pamela Bjorkman, California Institute of Technology, U.S.A.

10.00-10.30 Panel discussion: What is the path to broadly protective beta coronavirus vaccines? Imprinting and diversity of T and B cell repertoires.

All speakers

Discussant

Christian Gaebler, Charité – Universitätsmedizin Berlin, Germany

10.30-10.50 Break

SESSION 7

10.50-12.30 SARS-CoV-2 human challenge studies

Chair **Andrew Pollard**, University of Oxford, United Kingdom

10.50-11.10 Current experience

Chris Chiu, Imperial College London, United Kingdom

11.10-11.30 Establishing a SARS CoV2 human challenge model in previously infected subjects to identify immune correlates of protection

Helen McShane, University of Oxford, United Kingdom

11.30-11.50 Access to SARS-CoV-2 strains

Chris Chiu, Imperial College London, United Kingdom



National Institute
of Mental Health



CEPI



Vaccinopolis
University of Antwerp

11.50-12.30 Panel discussion: Using human challenge studies for identification and of correlates of protection. Creating a network for COVID-19 human challenge studies (objectives of a network, sites, lab, standardization, agencies, ...).

All Speakers

Discussants

Gagandeep Kang, Christian Medical College, Vellore, India (Remote)

Pierre Van Damme, Vaccine & Infectious Disease Institute,
University of Antwerp, Belgium

12.30-13.15

Lunch

13.15-14.00

Closing remarks, Conclusions and the Way Forward.